Feasibility of shortening intravenous antibiotic therapy for bronchiectasis based on bacterial load: a proof-of-concept randomised controlled trial

Pallavi Bedi, Manjit K. Cartlidge, Yang Zhang, Kim Turnbull, Samantha Donaldson, Andrea Clarke, Jane Crowe, Kadiga Campbell, Catriona Graham, Ruzanna Franguylan, Adriano G. Rossi, Adam T. Hill

Source: Eur Respir J, 58 (6) 2004388; 10.1183/13993003.04388-2020
Journal Issue: December

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Pallavi Bedi, Manjit K. Cartlidge, Yang Zhang, Kim Turnbull, Samantha Donaldson, Andrea Clarke, Jane Crowe, Kadiga Campbell, Catriona Graham, Ruzanna Franguylan, Adriano G. Rossi, Adam T. Hill. Feasibility of shortening intravenous antibiotic therapy for bronchiectasis based on bacterial load: a proof-of-concept randomised controlled trial. Eur Respir J, 58 (6) 2004388; 10.1183/13993003.04388-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Helium-hyperoxia a novel treatment for optimizing pulmonary rehabilitation: a randomized controlled trial
Source: Eur Respir J 2007; 30: Suppl. 51, 327s
Year: 2007

Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial.
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018


Pivot trial A multicentre randomised controlled equivalence trial comparing oral amoxycillin and intravenous penicillin for community acquired pneumonia in children
Source: Eur Respir J 2004; 24: Suppl. 48, 714s
Year: 2004

Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial
Source: Eur Respir J, 51 (1) 1701926; 10.1183/13993003.01926-2017
Year: 2018



Efficacy and safety of sequential three-step empirical therapy for chronic cough: a multi-center clinical study
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017

A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol
Source: Eur Respir J 2016; 48: 320-330
Year: 2016



Azithromycin for the treatment of cough in idiopathic pulmonary fibrosis: A randomized controlled cross-over pilot trial.
Source: Virtual Congress 2020 – Chronic cough: only symptom or disease?
Year: 2020




Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial
Source: Eur Respir J, 56 (6) 2002808; 10.1183/13993003.02808-2020
Year: 2020



Efficacy of a short course of oral prednisolone for acute preschool viral-wheeze: a double-blind randomised placebo-controlled trial with stratification for systemic eosinophil priming
Source: Eur Respir J 2003; 22: Suppl. 45, 388s
Year: 2003

RCT Abstract - The efficacy and safety of colistimethate sodium delivered via the I-neb in bronchiectasis: the PROMIS-I randomized controlled trial
Source: Virtual Congress 2021 – ALERT: bronchiectasis and COVID
Year: 2021



Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT?
Source: ERJ Open Res 2016: 00055-2016
Year: 2016



Long-term efficacy of a home-based airway clearance programme to improve cough severity in patients with bronchiectasis:a randomised controlled trial>
Source: International Congress 2019 – Advances in bronchiectasis and non-TB mycobacterial infections
Year: 2019




Open-label, randomized, comparative trial of the efficacy of levofloxacin versus clarithromycin SR therapy in complicated infectious exacerbation of COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 674s
Year: 2007

Supplementation of N-acetylcysteine as an adjuvant in treatment of newly diagnosed pulmonary tuberculosis patients: A prospective, randomized double blind, placebo controlled study
Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment
Year: 2013

Analysis of the efficacy of moxifloxacin for the treatment of bronchial colonization in COPD patients using microbial molecular typing: a randomized, double-blind, placebo-controlled study
Source: Annual Congress 2008 - Biomarkers and antibiotic treatment of exacerbations of COPD
Year: 2008


Safety and benefit of adjunctive systemic corticosteroid therapy in the management of severe, smear positive pulmonary tuberculosis (SSP-PTB); an interim analysis of a randomized controlled trial
Source: Annual Congress 2012 - Tuberculosis: clinical findings II
Year: 2012


A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen
Source: Eur Respir J 2001; 18: Suppl. 33, 189s
Year: 2001

A double-blind randomised controlled trial of protein supplementation to enhance exercise capacity in COPD during pulmonary rehabilitation: a pilot study
Source: ERJ Open Res, 7 (1) 00077-2021; 10.1183/23120541.00077-2021
Year: 2021



Experimental hookworm infection as potential therapy for asthma: a randomised placebo controlled trial
Source: Annual Congress 2009 - Epidemiology of atopy and asthma
Year: 2009

RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations
Source: Virtual Congress 2021 – ALERT: COPD
Year: 2021